J.P. Morgan analyst Anupam Rama has maintained their bullish stance on DAWN stock, giving a Buy rating today.
Anupam Rama’s rating is based on the promising potential of Day One Biopharmaceuticals’ product, Ojemda, particularly in the treatment of relapsed/refractory pediatric low-grade glioma (r/r pLGG). The analyst believes that the market has not fully appreciated the value of Ojemda, which could significantly impact the company’s growth and stock performance.
Furthermore, the ongoing pivotal phase 3 FIREFLY-2 tovorafenib trial in first-line pediatric low-grade glioma (1L pLGG) is progressing well, with full enrollment expected by the first half of 2026. This trial’s success could further enhance the company’s prospects, reinforcing the Buy rating at current stock levels.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $40.00 price target.